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Case presentation
A 33-year-old man received a cadaveric renal transplant at New
England Medical Center (NEMC). He first developed insulin-depen-
dent diabetes mellitus at age 11. Over the ensuing 22 years his diabetes
was complicated by diabetic retinopathy that required multiple laser
photocoagulation treatments and a vitrectomy of the right eye in 1974.
Peripheral neuropathy produced sensory deficits in all extremities, and
he had a "silent" lateral wall myocardial infarction; he had no episodes
of diabetic ketoacidosis or infection.
One and one-half years earlier he had been admitted to a local
hospital because of fatigue, weakness, and poorly controlled diabetes.
He was reported to have renal insufficiency and hypertension at that
time and was discharged after his diabetes was better controlled. Over
the following year he was hospitalized 7 times for poorly controlled
hypertension and congestive heart failure. Renal function progressively
deteriorated, and maintenance hemodialysis was initiated 6 months
before admission to NEMC. He was subsequently stable; both the
diabetes and hypertension were well controlled, and the patient had no
episodes of congestive heart failure or angina during thrice-weekly
hemodialysis treatments of 5 hours each and while taking 40 units of
NPH insulin daily, phosphate binders, and multivitamins. He did have
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one episode of uremic pericarditis, which was treated with increased
hemodialysis and antiinflammatory drugs.
Shortly after starting hemodialysis, he was evaluated at NEMC. He
had no suitable prospective living related donor and was placed on the
cadaveric transplant list 2 months after hemodialysis was begun. Six
months later he received a 4/4 HLA antigen-matched kidney. Postoper-
atively, the graft functioned well and the patient's urine output was 3 to
4 liters per day. The only initial problem was a widely fluctuating blood
sugar level that ranged from 46 to 504 mg/dl and required frequent
adjustments of his insulin dose. On postoperative day 2 his temperature
rose to 38.5° C. Thorough investigation over the next several days
revealed no source of infection. His graft continued to function well and
the BUN and serum creatinine levels fell to 48 mg/dl and 2.3 mg/dl by
the sixth postoperative day. He had daily fevers of 38° to 39° C, but no
source of infection could be found and no antibiotics were given.
On the seventh postoperative day, the serum creatinine level rose to
3.6 mg/dl and urine output fell. He was treated with "pulse" doses of
steroids and graft irradiation for presumed acute rejection. He did not
respond to this anti-rejection regimen and the serum creatinine level
continued to rise. A second steroid pulse was considered but not
administered because his transplant rejection was believed irreversible.
His steroid and immunosuppressant drugs were tapered starting on the
14th postoperative day, and hemodialysis was reinstituted. A transplant
nephrectomy was to be done on the 15th postoperative day, but during
induction of anesthesia the patient developed complete heart block
followed by ventricular tachycardia and fibrillation. He was quickly
resuscitated, and an electrocardiogram revealed inferior ischemic
changes. Hemodialysis was reinstituted after cardiac enzyme studies
showed no myocardial injury. One week later the patient underwent
successful transplant nephrectomy and A-V fistula repair. The remain-
der of his hospital stay was uneventful except for severe depression,
and he was discharged on the 31st postoperative day.
He returned to his local dialysis unit for continued maintenance
hemodialysis. He was extremely depressed and manifested poor adher-
ence to fluid and dietary prescriptions with frequent episodes of volume
overload. Six weeks following discharge from NEMC he died en route
to his local hospital, presumably because of acute myocardial ischemia
with fluid overload.
Discussion
DR. ELI A. FRIEDMAN (Professor of Medicine, and Chief,
Renal Disease Division, Downstate Medical Center, Brooklyn,
New York): About one-half of type-I diabetics (formerly termed
juvenile diabetics), develop renal failure in a mean of 20 years.
At present, approximately one in four patients beginning thera-
py for end-stage renal disease (ESRD) in the United States is
diabetic. Diabetics face a more morbid course during dialytic
therapy as well as after kidney transplantation, and they have a
substantially greater mortality rate than do age- and sex-
matched nondiabetics. We can estimate the magnitude of the
economic burden of diabetic nephropathy by dividing the yearly
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federal cost for the ESRD program in 1981, which was about
$1.4 billion, by four; thus, the United States spends a minimum
of $300 million annually on diabetics with uremia. But, because
diabetics require more physician care, and longer and more
frequent hospitalizations than do nondiabetics, the cost for their
treatment is even greater than this minimum estimate.
In analyzing the course of the patient under consideration
today, I will review the natural history of renal damage in
diabetes and then discuss therapeutic options once uremia
supervenes. Finally, I will present evidence suggesting that
glomerulopathy is induced by hyperglycemia and therefore may
be prevented if blood sugar is maintained at normal levels.
The story of the patient under discussion today began, as is
not unusual in type-I diabetics, with his 20th year of insulin
dependence, when he was hospitalized for renal insufficiency
and hypertension. It is stated that when he was discharged from
the hospital, his diabetes "was better controlled," although we
are provided with no specific documentation that this was so.
Successful regulation of blood glucose in insulinopenic and
ketosis-prone type-I diabetics was, in the past, more art than
science. If one were to poll any group of physicians concerning
their concepts of the limits of "good control" of diabetes in a
patient with type-I diabetes, the wide range of responses would
illustrate the extent of confusion and imprecision regarding
appropriate management of this disease. Whereas the selection
of therapeutic approaches made little difference in the past
because none was both efficacious and practical, recent techni-
cal advances have made it possible to achieve sustained eugly-
cemia for many patients. Most important, had this patient
received from the onset the kind of treatment now available for
newly diagnosed diabetes, his multiple complications might
well have been prevented. I will attempt to support this
conjecture later.
Diabetics risk developing renal complications from many
different causes, as noted in Table 1. I will not discuss the
severe consequences of urinary tract infection that affect dia-
betics except to observe that each of 5 patients with renal
abscesses whom I have treated have been diabetics. Similarly,
although renal papillary necrosis does occur in ethanol and
analgesic abusers and in patients with sickle trait, the majority
of patients with this complication in my experience have been
type-I diabetics.
Natural history of diabetic renal disease. Our knowledge of
the natural history of diabetic nephropathy is restricted to type-
I diabetes. We can only speculate that the sequence of patho-
logic events is similar in the type-I! variety (previously called
maturity-onset diabetes). Difficulty in establishing a date of
onset of hyperglycemia and the paucity of sequential renal
biopsies in patients with type-I! diabetes preclude more than a
guess as to the correlation between severity of microvasculopa-
thy and altered renal function. Glomerulosclerosis, the renal
lesion characteristic of diabetic microangiopathy, is found in
uremic patients with both types I and II diabetes (Fig. 1).
Kimmelstiel and Wilson, in a retrospective autopsy study of 8
diabetics aged 48 to 63 years, first detected nodular intercapil-
lary glomerulosclerosis more than 40 years ago [1]; this finding
is now recognized as a specific lesion that is present in about
one-half of all diabetics. The more prevalent, diffuse form of
intercapillary glomerulosclerosis was described more recently;
this lesion can occur alone or in conjunction with nodular
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glomerulosclerosis. The earliest change in glomerulosclerosis is
an increase in mesangial matrix and thickening of the glomeru-
lar basement membrane (GBM) (Fig. 2). When type-I diabetes
is first diagnosed, renal biopsies do not show ultrastructural
thickening of the GBM. This finding, albeit a negative one, is
important in refuting the contention that microangiopathy is
genetically predestined [2]. If GBM thickening occurs only in
diabetics who are hyperglycemic, then even though a tendency
toward hyperglycemia is inherited, microvascular disease may
not be inevitable.
Viberti recently reviewed the renal functional alterations in
type-I diabetics that can be detected years before nephropathy
becomes clinically evident [3]. Patients with newly diagnosed
type-I diabetes [4] and adults with long-standing type-I disease
[5] have supranormal glomerular filtration rates, approximately
140% of that of age- and sex-matched nondiabetic control
subjects. Although renal plasma flow originally was thought to
be elevated in patients with type-I disease [4], recent studies
show it to be either unchanged or depressed in the patients with
an increased GFR [5]. The elevated GFR is partially corrected
when hyperglycemia is first regulated, although supranormal
values persist for at least the first decade of insulin dependence
[6].
Proteinuria is the first sign of glomerular damage. Type-I
diabetics without proteinuria after 5 to 10 years can be pro-
voked to excrete protein by treadmill exercise or other stress
that does not cause proteinuria in nondiabetics [7]. Depending
on the technique used for measurement, the prevalence of
proteinuria has been reported to be as high as 100% in type-I
diabetics after 6 months to 39 years of insulin use in one study
[7], or less than 10% in the first 10 years in another study [8].
Newly diagnosed type-Il diabetics have constant urinary albu-
min excretion as shown by Keen et al [9], but type-I diabetics at
the onset of their disease are proteinuric only when in poor
metabolic control [10]. This difference may reflect the presence
of nephro sclerosis in older type-Il diabetics who may have had
years of previously undetected carbohydrate intolerance. Fur-
ther study of the influence of exercise on proteinuria in diabetes
is likely to be fruitful. We know that the amount of postexercise
proteinuria is determined both by the basal protein excretory
rate and the intensity of exercise. Exercise-induced proteinuria
in diabetics without proteinuria at rest might be the first clue to
glomerulosclerosis.
Table 1. Diabetes-induced renal disorders
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Fig. 1. Nodular intercapillary glomeruloscierosis. Advanced stage in type-I diabetic after 19 years of insulin use. Almost total obliteration of
capillary loops has taken place accounting for a serum creatinine concentration of 11 mgldl.
The proportion of type-I diabetics who exhibit proteinuria
increases steadily as a function of duration of insulin depen-
dence. By the 20th year of insulin treatment, about one-half of
patients have continuous proteinuria [121. Fixed proteinuria is
an ominous sign; according to Mogenson, in diabetics with
fixed proteinuria and a normal GFR, the GFR will subsequently
decline at the rate of approximately 11 mI/mm/year [13]. An
elevated serum creatinine concentration follows the appearance
of proteinuria by an average of about one year, although there is
wide variability. Some patients maintain a normal serum creati-
nine level after 5 or more years of proteinuria [14]. Urinary
protein losses can exceed 10 to 20 g/day and result in hypopro-
teinemia and a typical nephrotic syndrome.
Other than fluid retention, there are few clinical conse-
quences of the nephrotic syndrome secondary to glomeruloscle-
rosis. Nevertheless, in my experience, nephrotic diabetics
appear sicker than nondiabetics with proteinuria of equivalent
degree. Indeed, the diabetics are often cachectic. Diabetics
retain extracellular and intravascular fluid at serum albumin
levels that do not induce fluid accumulation in nondiabetics.
Fluid overloaded diabetics with glomerulosclerosis may have a
serum albumin concentration of 2.8 to 3.4 g/dl. Whether margin-
al cardiac decompensation or more permeable capillaries are
responsible for this phenomenon remains to be clarified.
According to a study by Rutherford et al, azotemia super-
venes in type-I diabetics after a mean of 17.3 years of insulin
dependence; there follows an exponential decline in renal
function that lasts a mean of 3 years [1511. The rate of loss of
GFR is relatively constant for each patient and forms a straight
line when the reciprocal of the serum creatinine concentration
is plotted against time [16]. Glomerulosclerosis usually takes 20
years to progress from initiation of insulin dependence to the
onset of uremia (Fig. 3), This patient's kidneys failed 22 years
after he received his first insulin dose; glomerulosclerosis was
the predictable finding at necropsy.
Recently, the belief that renal insufficiency was the inevitable
and unavoidable consequence of long-duration, type-I diabetes
has been replaced by growing excitement over the possibility
that vigorous therapy might retard progression of glomerulo-
sclerosis. This view has been nurtured by two clinical observa-
tions: (1) aggressive reduction of blood pressure in hypertensive
type-I diabetics with renal insufficiency slows deterioration of
GFR, as shown by Mogenson [17]; and (2) in large but uncon-
trolled clinical trials of strict regulation of blood glucose con-
centration, Cahill has noted a substantive decline in the rate of
development of uremia [181.
Management of uremia. Management of the uremic diabetic
patient entails more than treatment of renal failure. Nearly all
type-I diabetics have serious retinopathy when renal insuffi-
ciency first develops; in fact 50% are blind or have lost some
p
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Fig. 2. Mesangial and basement membrane changes of diabetic nephropathy. Composite electron photomicrograph contrasting normal and
diabetic changes. Upper left shows normal glomerular basement membrane (BM) with finger-like epithelial foot processes in nondiabetic adult.
Upper right shows thickened, dense glomerular basement membrane and fused foot processes after 11 years of type-I diabetes. Lower left shows
normal mesangial (M) region of glomerulus in nondiabetic adult. Lower right shows that early nodular glomerulosclerosis located in mesangium
nodule (MN) is composed of mesangial matrix with remnants of mesangial cell (MC) debris in type-I diabetic adult after II years. C indicates
capillary lumen; E indicates endothelial cell.
vision l9]. The coexistence of renal insufficiency, cataracts,
glaucoma, and, most important, proliferative retinopathy with
retinal and vitreous hemorrhages comprises what we have
termed a "renal-retinal syndrome." Collaboration with an
experienced ophthalmologist is vital for optimizing rehabilita-
tion of uremic type-I diabetics. The combination of properly
timed laser therapy (panretinal photocoagulation) and extrac-
tion of clot and fibrous tissue from the vitreous chamber
(vitrectomy) now allows the majority of insulin-dependent
diabetics to retain adequate (ambulatory) vision throughout
their course, as did today's patient. Many patients also require
medical attention for coincident sensory and motor neuropathy,
peripheral vascular insufficiency, inadequate cerebral perfu-
sion, and deterioration in myocardial function.
As uremia becomes the dominant clinical problem, patients
and their families often despair and may even panic unless a
therapeutic strategy has been devised in advance. Prior to their
referral to a nephrology program, azotemic type-I diabetics
typically have been managed solely for their eye problem or for
their heart failure by subspecialists who fail to communicate
with each other. As a consequence, the patient may be given
conflicting opinions about the optimal diet and may be given
drugs that have adverse interactions. By the time uremia
becomes manifest, the type-I diabetic may be forced to spend
much time and money traveling from one subspecialist to
another.
Optimal management of uremic diabetics by dialysis or renal
transplantation requires development of a team plan in which a
single physician, clearly identifiable as the patient's doctor,
follows through in integrating needed services. Full disclosure
of available therapeutic options and the chances of success
fortifies the patient against future stresses. In managing pro-
gressive glomeruloscierosis, special attention must be directed
at (1) avoiding iatrogenic renal injury by limiting the use of
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contrast media, nephrotoxic drugs, and urethral instrumentation;
(2) controlling hypertension; (3) monitoring cardiac status; (4)
manipulating protein, sodium, and caloric intake in recognition
of the changing but conjoint constraints of diabetes and renal
insufficiency; (5) adjusting insulin dose downward as renal
disease worsens; and (6) as in all patients with advancing renal
failure, minimizing uremic osteodystrophy by appropriate treat-
ment of altered phosphate and calcium metabolism.
As renal reserve declines, a decision must be made regarding
therapy beyond conservative care (Tables 2 and 3). For the
nondiabetic, dialysis usually can be safely delayed so long as
the GFR exceeds 5 mllmin. By contrast, type-I diabetics are
often severely symptomatic when the GFR falls to 10 mI/mm,
and therapy must be started earlier (personal observation).
Little information was provided about this patient's pretrans-
plant therapeutic regimen other than that he responded well to
treatment for hypertension and cardiac failure. The protocol
does not distinguish between actual myocardial failure and
volume overload. My guess is that fluid retention and hyperten-
sion contributed more to the patient's illness than did true
cardiac failure.
The first decision to be made by the uremic diabetic patient is
whether to be treated at all for renal failure. A blind, hemipare-
tic, double amputee might, after discussion with the family,
decline the chance for a few additional months or years of life
on the grounds that there is little likelihood of enjoyable life
even with the best-imagined result, Informed uremic diabetics
who do opt for aggressive treatment can be offered a variety of
very different therapies, all of which can extend life under some
circumstances (Tables 2, 3, 4).
Dialysis in diabetic patients. Repetitive hemodialysis for
diabetic nephropathy, first attempted by Avram [20], has be-
come the most frequently used method for sustaining life in
type-I diabetics. In the early 1970s, the annual mortality for
hemodialyzed patients with type-I disease exceeded 60%, and
50% of the surviving patients became blind [211. By the end of
that decade, however, appreciation of the importance of control
of hypertension and intravascular volume overload improved
the lot of dialyzed patients, half of whom now live for at least 3
years [22]. Still, it is disturbing that fewer than one in four
hemodialyzed diabetics is able to return to work, school, or
home responsibilities [23]. Great Britain and other countries
with underfunded health care systems consider the outlook for
hemodialyzed diabetics so poor that such patients are excluded
from treatment [24]. In our experience, however, some hemo-
dialyzed, type-I diabetics do work, raise families, and lead
vigorous lives, thus precluding a pessimistic prediction for
every diabetic who is about to begin dialysis.
Yet it is true that even in series with the best results, survival
of type-I diabetics 2 years from the initiation of dialysis is about
20% worse than that for nondiabetics [22]. Death in hemodia-
lyzed diabetics usually is caused by cardiovascular disease
(30% to 70% of patients). Cerebrovascular accidents, infection,
and uremia or withdrawal from dialysis each account for about
15% of deaths. After the failure of a kidney transplant, uremia
was treated in the patient under discussion by maintenance
hemodialysis. The extremely depressed dialysis patient may
give up, pay little attention to dietary or fluid restrictions,
become progressively withdrawn, and begin a downward spiral
that may terminate in suicide. In the summary of this patient's
course, no mention was made of plans for a second transplant,
home hemodialysis, or some other therapeutic change that
might have given the patient reason to anticipate more than his
poor adaptation to institutional dialysis. For diabetics who
become hypotensive during and after fluid removal by ultrafil-
tration, consideration of transfer to hemofiltration may be
advisable [25]. Very few diabetics have undergone maintenance
hemofiltration, but the initial experience is encouraging.
In early 1982, approximately 6000 Americans were being
treated for uremia by peritoneal dialysis. As a group, type-I
diabetics have not responded well to intermittent (thrice week-
ly) peritoneal dialysis; these patients have achieved one-year
survival rates of only 22% to 50% [261. Limited survival
probably results from extreme hyperglycemia induced by dialy-
sate glucose concentrations of 1500 to 4500 mg/dl and fluid
retention. More recently, the combination of CAPD and the
addition of insulin to dialysate, as suggested by Crossley and
Kjellstrand [27], has substantially increased the one-year sur-
vival to more than 80% [28]. Advantages of CAPD over
hemodialysis include rapid training (under one week), lack of
need for a recycling machine, minimal cardiac stress, and
superior blood glucose regulation. Trials now in progress will
ascertain whether these advantages will outweigh the difficul-
ties that stem from recurrent peritonitis and from the enervation
related to a seven-day-a-week therapeutic regimen.
Transplantation in diabetics. In my opinion, kidney trans-
plantation has emerged as the preferable therapy for type-I
diabetics. A functioning renal allograft permits a degree of
rehabilitation unobtainable by even the best hemodialysis. Until
the past 3 years, however, one's chance of dying despite
receiving a cadaveric kidney (35% in 2 years) discouraged
many informed uremic patients from choosing transplantation
over dialysis. For the type-I diabetic who typically experienced
a series of disasters on dialysis, as did the patient under
discussion today, the decision to "try a transplant" is less
difficult. In such patients, the choice often appeared to be
10 15
Years of insulin dependence
Fig. 3. Natural history of diabetic nephropathy. Note that a normal or
supernormal GFR is usual throughout most of the course of type-I
diabetes. Proteinuria typically precedes azotemia. The interval between
onset of insulin dependence and end-stage renal failure is typically 20
years.
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Table 2. Selecting optimal therapy for diabetics with uremia
Cures uremia for duration of graft function
Stabilizes retinopathy
Permits long intervals (months) away from treatment facility
Reverses neuropathy
Best rehabilitation
Long-term survival
Avoids major surgery
Minimizes burden on cardiovascular system
Facilitates glucose regulation when insulin is added to
dialysate
Adaptable to home care (intermittent PD or CAPD) in se-
lected patients
Hemodialysis Avoids major surgery
Permits care by experienced staff
Available in most countries
Disadvantages
Steroids complicate glucose control
Risk of infectious complication
High mortality in cadaveric graft recipients
Risk of developing diabetes in familial donors
Not applicable to elderly or patients with cardiovascular
instability
Gomerulosclerosis can recur
High mortality
Retinopathy progresses
Limited long-term success
Poor rehabilitation
Retinopathy may progress
Mortality equivalent to that for cadaveric graft recipients
Inexorable failure to thrive" syndrome in about 25% of
patients
Table 3. Suggested therapy in uremic diabetic patients
Age range (years)
Renal
transplant
Peritoneal
dialysis Hemodialysis
18to44 ++a ? +b
45 to 65 Selected
patients + +
Over 65 (or presence of
intractable heart
failure) — + +
++ refers to strongly recommended, especially if family donor
available
b + refers to recommended
— refers to not recommended
between kidney transplantation and imminent death. Najarian
appreciated this dilemma even though he collaborated with
nephrologists who provided excellent hemodialysis [29, 30].
Gradually, a combination of azathioprine, prednisone, antithy-
mocyte globulin, and splenectomy was devised that much
improved the prospects for uremic patients undergoing trans-
plantation: one recent series of cadaveric allografts in type-I
diabetics produced an astonishing 2-year functional graft sur-
vival of 85% [311. Our series, although uncontrolled, convinced
me that kidney transplantation (Fig. 4) offered a better chance
of life for 2 years than did hemodialysis. The posttransplant
course in diabetics is associated with all the complications that
occur in nondiabetics, plus a higher incidence of infection,
lower limb amputation, and bladder malfunction. We have
learned that diabetics need not become blind after a transplant
provided that adequate vision was present at the time of kidney
transplantation, and also provided that the renal allograft func-
tions. Approximately 4 of 5 recipients will have stable or
improved vision 3 years after transplantation [32, 33].
As in nondiabetics, transplantation of a well-matched kidney
from a donor in the family offers the best chance of survival and
ultimate rehabilitation. For a kidney transplanted from a haplo
type-identical sibling to a type-I diabetic, the 2-year patient
survival exceeds 80%, with graft function in about 70% [301. A
cadaveric kidney offers the next best chance for rehabilitation.
Cadaveric graft recipients do not survive as long as do patients
who receive kidneys from a sibling; about 60% live 2 years, with
graft function in about 50%.
Tables 2 and 3 compare key factors governing selection of
treatment for a type-I diabetic with end-stage renal disease. Not
all clinicians would concur with my preference for a transplant.
Kjellstrand, for example, emphasized a recent improvement in
the survival rate for hemodialysis patients and attributed this
success to more vigorous control of hypertension and volume
overload; he argued that in many instances hemodialysis is
preferable to a cadaveric renal transplant [34].
Returning to our patient, we note that although he received a
"perfect" 4 antigen matched cadaver kidney, it functioned for
only 14 days and was lost to a vigorous rejection episode
despite graft irradiation and high doses of steroids. This kind of
experience confirms our own suspicion that the matched HLA
antigens comprise only part of the antigen system that deter-
mines our individuality, Graft survival at one year in the best
and worst HLA-matched donor-recipient pairs (in cadaveric
transplantation) in this country probably differs by no more
than 10%.
The history of prior blood transfusions was not included in
the case description, but this information is vital for assessing
transplant results. Opelz and Terasaki initially detected the
effect of blood transfusions: graft survival is directly propor-
tional to the number of transfusions the patient has received
prior to cadaveric transplantation [351. Graft recipients who
have received 10 or more transfusions show an approximately
20% greater rate of graft retention at one year than do untrans-
fused patients of the same age and sex. Since numerous groups
have confirmed the benefit of transfusion, many transplant
centers prescribe elective pretransplant transfusions in the 2
months before a dialysis patient is placed on an active recipient
list. Potential recipients of a kidney from a living related donor
against whom there is a strong mixed lymphocyte reaction may
benefit from pretranspiant donor-specific blood transfusions.
Feduska et al used donor-specific transfusions in 20 type-I
uremic diabetics and found that 3 patients (15%) developed
Advantages
Renal
transplantation
Peritoneal
dialysis
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Table 4. Comparison of diabetic control before and after close monitoring of blood glucose and split doses of insulin
Age of
patient Therapy
Daily glucose
before (mg/dl)
Daily glucosea
after (mgldl)
Hemoglobin A1c
before
Hemoglobin A1cb
after
35 Transplant 181—350 100—180 — —
48 Transplant 3 1—152 100—180 9.0 7.0
37 Transplant 96—314 80—80 9.3 6.8
51 Transplant 280—612 120—120 7.9 7.0
41 Transplant 96—224 110—120 10.5 9.7
54 Hemodialysis 160—375 80—180 12.9 8.1
54 Hemodialysis 78—162 80—120 9.1 6.8
44 Hemodialysis 192—495 150—180 10.8 9.4
Determined by Chemstrip
b Lowest value achieved during 6 months of self-monitoring
W Nondiabetic newer immunosuppressive agents that permit the use of lower
doses of steroid than does azathioprine, have elicited great
•9 interest for their potential value in diabetic renal graft recipi-
___________________
ents. In 1982, state-of-the-art immunosuppression should per-
8 mit greater than 50% of cadaveric kidney grafts to function for
at least 2 years in optimally treated type-I diabetics.
Rationale for close control of blood glucose levels. I would
like to close with the reasoning behind my contention that
glucose regulation should be the pivotal component in any
strategy for diabetic management, irrespective of the patient's
renal function. Over the past 3 years, much has been learned
27 jc about possible mechanisms by which hyperglycemia can induce
glomerular injury, and considerable evidence indicates that
keeping blood glucose within the normal range can be protec-
tive. Fast hemoglobin, also termed hemoglobin A1c, is a form of
hemoglobin synthesized in proportion to the time-averaged
blood glucose concentration [39]. Hemoglobin A1c, which can
be measured in a commercially available, disposable chroma-
tography column, can be used as a guide to insulin therapy.
Also marketed recently are simplified reagent strips that permit
patients to measure their own blood glucose levels several times
6 4 daily. Guided by frequent glucose determinations, multiple-
dose [40] or continuously infused [41] insulin regimens have
approached Elliot Joslin's visionary ideal of an insulin-depen-
dent patient who is euglycemic around-the-clock.
27 Observations made in nearly eugylcemic, type-I diabetics
force revision of our concepts about what is and what is not an
inherent (genetic) part of diabetes. With blood glucose levels
kept within normal limits, virtually every aspect of altered
metabolism in the diabetic—from hyperlipidemia to abnormal
activity of counterregulatory hormones—is corrected. Euglyce-
mic pregnant women with diabetes have babies without polyhy-
dramnios or neonatal distress [41]. At least 100 papers now
support the argument that a sustained normalization of blood
glucose is good for the type-I diabetic both biochemically and
clinically. But what effect does euglycemia have on the glomer-
ulus in a diabetic patient?
The rat with streptozotocin-induced diabetes, like the human
with type-I diabetes, develops increased kidney, glomerular,
and mesangial size; these changes can be prevented or correct-
ed by insulin treatment or islet of Langerhans transplants [42].
When rat kidneys with histopathologic glomerular changes
similar to glomerulosclerosis are transplanted into nondiabetic,
isogeneic recipients, glomerulopathy is reversed [43]. Critics
have disparaged conclusions drawn from these experiments
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Fig. 4(A) Kidney transplants in diabetics. Actuarial plot of survival of
patients with renal grafts from living related donors at Downstate
Medical Center for the past 2 years. Mortality in diabetic recipients is
about 11% greater at 2 years than in nondiabetics (courtesy Dr.
K. M. H. Butt). (B) Cadaveric graft function in diabetics and nondia-
betics at Downstate Medical Center. At 2 years, about 50% of diabetics
retain their grafts, but as a group these patients do less well than do
nondiabetics (courtesy of Dr. K. M. H. Butt).
antileukocyte antibodies against the donor, thus precluding use
of a graft from that individual [36]. Of 16 patients who subse-
quently received a kidney from their blood donor, graft survival
was 93% and 84% at 1 and 3 years respectively.
Diabetics are exceptionally vulnerable to the toxic effects of
large doses of methylprednisolone, which often are adminis-
tered to reverse graft rejection. Cyclosporin A [37] and mono-
clonal antibody against thymus-derived lymphocytes [38], both
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because of the differences in appearance of rat and human
glomeruloscierosis. In 1981, however, two experiments per-
formed in Minneapolis added credence to the postulate that
hyperglycemia causes glomerulopathy. In the first study,
Mauer showed that when blood sugar levels are rigorously
controlled in type-I diabetic recipients of nondiabetic donor
kidneys, recurrent glomeruloscierosis is delayed or avoided
[44]. In the second study, Najarian observed that glomerulo-
sclerosis regressed after pancreatic transplantation in a diabetic
patient who had received a kidney transplant from a nondiabet-
ic donor and had developed recurrent glomerulosclerosis in the
graft [45].
How can a nephrologist use the hypothesis that diabetic
nephropathy is a glomerulopathy resulting from hyperglyce-
mia? I believe the responsible physician should initiate an
intensified effort to achieve euglycemia in all diabetics with
renal insufficiency. There is little reason to consider abnormally
wide swings in blood glucose any less undesirable in diabetics
with failed kidneys than in patients without azotemia. Indeed,
one could hypothesize that an explanation for reduced survival
in diabetics treated by hemodialysis and kidney transplantation
is poor regulation of blood glucose. Representative blood
glucose levels in a conventionally controlled type-I diabetic on
hemodialysis (Fig. 5) and a type-I diabetic recipient of a
cadaveric kidney (Fig. 6) illustrate the usual extent of inade-
quate glucose regulation. We conducted a pilot study of "tight"
glucose control in S renal transplant recipients and 3 hemodialy-
sis patients; we used split insulin doses and had the patients
monitor their blood glucose levels [46]. Improved control was
confirmed by a reduction in hemoglobin A1c (Table 4). In
principle, incorporation of a tight glucose control plan in the
care of type-I transplant recipients should prove salutary in two
important ways: (1) All the subjective benefits of euglycemia
noted in nonazotemic diabetics should be realized; and (2)
Euglycemia might protect the renal transplant from recurrent
glomerulopathy.
It is reassuring to those about to embark on trials of tight
control of blood sugar in diabetic renal transplant recipients that
careful glucose regulation after kidney transplantation does not
seem to impose any negative consequences.
Questions and answers
DR. JOHN T. HARRINGTON: Before nirvana arrives when all
blood sugars are normal and we don't have patients with
diabetic nephropathy anymore, we still have enormous prob-
lems to deal with. How do you decide, in an individual patient,
among the various options available for the diabetic patient with
total renal failure?
DR. FRrnDMAN: As is true for the nondiabetic uremic patient,
no single therapeutic approach is endorsed by physicians treat-
ing diabetics with total renal failure. To illustrate this point, it is
instructive to observe the difference of opinion between medi-
cal and surgical members of the transplantation team at the
University of Minnesota, the institution with the largest and
most scholarly experience in treating diabetics with uremia.
Najarian, who is surgeon-in-chief, cites his most recent series of
cadaveric transplants in type-I diabetics to support his conten-
tion that renal allografting is the treatment of choice: a remark-
able 85% 2-year functional graft survival was achieved [31]. On
the other hand, Kjellstrand, who directed medical management
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Fig. S. Diabetic on hemodialysis. Glucose control by conventional
therapy is poor in this uremic 43-year-old type-I diabetic woman. None
of the diabetics whose glucose level was monitored during a dialysis day
had what could be termed satisfactory control. Note severe hypoglyce-
mia at 11:30 P.M. on day 1 (courtesy C. S. Levitz).
(including hemodialysis) for Najarian's patients, calculated that
his latest series of type-I diabetics on maintenance hemodialysis
had a higher survival rate than did a reported series of cadaveric
kidney recipients [34]. The absence of any age-matched pro-
spective trial of alternate patients treated either by dialysis or
transplantation precludes a definitive answer as to which offers
better survival rates. My guess is that the greatest chance of
living 5 years is offered by a related donor transplant. Lacking
such a donor, survival after a cadaveric kidney graft is probably
worse in the first year than for a year of maintenance hemodial-
ysis. Three years later, I believe that there is probably little
difference in the survival rate afforded by the two treatments.
Information as to which option yields more complete rehabilita-
tion is sketchy, although my experience indicates that when a
transplant functions, the diabetic attains a level of well-being
unreachable by dialysis. Whether CAPD will become an appro-
priate option remains to be seen.
Although I like to believe that my patients exercise free will
in selecting their therapy, I recognize the difficulty in obtaining
truly informed consent [47], and I usually communicate my bias
as to which option I prefer. For type-I diabetics under 50 years
of age, a living donor transplant is my first choice, followed by a
cadaveric kidney graft and, last, hemodialysis performed at
home. Older patients are started on dialysis and transferred to
the transplant group should they deteriorate or fail to improve
on dialysis.
DR. HARRINGTON: You mentioned in passing that there is
some new information about the efficacy of CAPD in diabetic
patients. Could you elaborate?
DR. FRIEDMAN: A major potential advantage of CAPD in
diabetics is reduced stress on a heart often affected by cardio-
myopathy. Whereas only 2 years ago, the 2-year mortality rate
for type-I diabetics treated by intermittent peritoneal dialysis
was greater than 65%, Oreopoulos [48] and Flynn in separate
trials of CAPD now in progress have been able to keep over
50% to 60% of patients alive for at least 2 years. Both teams
believe that the addition of insulin to dialysate eases diabetic
control and permits tolerance of the large glucose load present
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Fig. 6. Diabetic renal transplant recipient. This 42-year-old type-I
diabetic was poorly controlled on a 2-dose insulin regimen. During
rejection when methylprednisolone was administered, plasma glucose
concentration reached 1100 mgldl (courtesy C. S. Levitz).
in dialysate at concentrations of 1500 to 4500 mg/dl. Should
these favorable results continue, the proportion of type-I dia-
betics treated by CAPD can be expected to rise substantially.
Intraperitoneal infusion of insulin may promote a more nearly
normal glucose metabolism than do either the subcutaneous or
intravenous routes. Stephen, in a study in progress, is testing
the hypothesis that continuous intraperitoneal infusion of insu-
lin even may prove beneficial to type-I diabetics prior to the
development of end-stage renal disease. After 6 months, Ste-
phen has noted sustained euglycemia, good patient acceptance,
and a reduction in daily protein excretion. Within 3 years, I
anticipate that sufficient data will be in hand to provide for a
more precise response as to the place of CAPD as therapy for
uremic diabetics.
Dg. SANG CHO (ChieJ Transplantation Service, NEMC): In
our transplantation program, we haven't used the kind of tight
control of blood sugar you have talked about in diabetic
recipients. Are there any data indicating that the rate of
progression of the vascular disease is faster in diabetic patients
receiving hemodialysis than in those who have a functioning
kidney transplant?
DR. FRIEDMAN: Serious vascular disease can progress in
both hemodialyzed and transplanted diabetics. Amputation of a
digit or limb is required in about 15% to 20% of transplant
recipients [49], but only in about 5% of dialysis patients. There
is no study quantifying the relative risk of stroke, heart attack,
and limb loss with both therapies. My impression is that more
transplant recipients suffer limb loss, especially of the lower
extremity, whereas more dialysis patients suffer stroke and
heart attack.
DR. CH0: As newer forms of itumunosuppression come
along, such as cyclosporin A and monoclonal antibodies [38],
we will almost certainly, as you suggested, depend less on
steroids than we do now. That may change our view of the
benefit of transplantation in diabetic patients in the near future.
DR. FRIEDMAN: Dr. Cho, I am very enthusiastic about the
imminent changes that I foresee in the transplant regimen of
diabetic patients. Reviewing the changes in immunosuppression
effected over the pastS years, I have become convinced that the
lesson that "less is better" has been well learned. Elimination
of very large doses of methylprednisolone (1000 mg or more
daily) and rapid lowering of the daily prednisone dose to 30 mg
or less by the second posttransplant month have been rewarded
by increased patient survival rates with no forfeiture of graft
function. If we reflect on the art of immunosuppression for
organ grafting, it is instructive to appreciate that few controlled
drug trials were performed and that the number of animal
experiments in other than rodents is sparse. We don't know, for
example, whether we can safely discontinue giving azathioprine
in recipients with stable graft function after a year, or whether
steroids are equally effective but less toxic if administered
every other or every third day rather than daily as is our current
approach. Other components of our transplantation regimen are
also followed in the absence of scientific validation. To under-
score this view, consider that controlled trials have not sus-
tained the proposed rationale for giving large doses of methyl-
prednisolone or subjecting recipients to local graft irradiation.
We are pragmatists by default. Now that reports of equal graft
function and better patient survival with fewer drugs are
appearing, the outlook for patients should continue to improve.
DR. DONALD HRICIK (Chief Medical Resident, NEMC): Is
there evidence in humans that strict control of hyperglycemia
can reverse or retard the progression of diabetic nephropathy
after renal insufficiency and progressive azotemia have devel-
oped?
DR. FRIEDMAN: There is little more than impression to
answer this question. Obsolescent glomeruli will not return to
life. Extrapolating from the observation that renal deterioration
can be slowed by treatment of hypertension, it is tempting to
infer that some partially damaged glomeruli might remain viable
if protein denaturation (glycosylation) can be stopped by estab-
lishment of euglycemia. Because a few proteinuric patients
begun on an insulin pump subsequently have sustained vitreous
hemorrhages, we must admit that damaged blood vessels may
continue to express their injury.
DR. COHEN: Would you go so far as to suggest that we could
completely avoid the microvasculopathy if we could really
achieve tight control of blood sugar in every diabetic?
DR. FRIEDMAN: Yes, Although other metabolic or unrecog-
nized genetic factors might contribute to organ damage in the
type-I diabetic, there seems to be little evidence to suggest that
the glomerulopathy is any more than a response to glycosyla-
tion and other secondary effects of hyperglycemia. Why should
this be an unreasonable hypothesis? There are numerous exam-
ples of a single metabolic defect inducing multisystem disease;
Fabry's disease, cystinosis, and cystinuria immediately come to
mind.
Consider how we have altered our views about the pregnant
diabetic patient. By careful induction of euglycemia, all the
terrible maternal and fetal complications that usually made
pregnancy a disaster in such patients have been eliminated.
Note further the prevention of diabetic glomerulopathy in
nondiabetic human kidneys transplanted into diabetics as
shown by Mauer and associates [44]. If native kidneys behave
as allografted kidneys in their response to environmental
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glucose, then the conclusion that diabetic glomerulopathy is a
preventable disease seems inescapable.
DR. COHEN: How would you define tight control? In other
words, what is euglycemia?
DR. FRIEDMAN: Restricting blood glucose variation through-
out the day to a range of about 70 to 140 mgldl is the objective of
modern control regimens. We have learned from the careful
monitoring of pregnant type-I diabetics that even narrower
limits, of approximately 60 to 100 mgldl, can be established for,
and tolerated by, highly motivated patients.
DR. CH0: I would agree that tight control of blood glucose in
the early phase of the disease might prevent the vascular
complications from occurring, but it might not arrest the
progression of vascular complications when tight control of
blood sugar is achieved at the later stage of diabetes mellitus. A
significant number of recipients of functioning pancreas trans-
plants died of multiple vascular complications even though the
blood sugar level was maintained in the normal range after
pancreatic transplantation.
DR. FRIEDMAN: Gliedman's pioneer experiments in pancreat-
ic transplantation are difficult to interpret on either side of the
tight control debate. Gliedman did show that a pancreas could
be transplanted and restore euglycemia [50]. It was not recog-
nized until a decade later, however, that reduction of high blood
pressure was as important to longevity as was establishment of
euglycemia [17]. There has been a great resurgence of interest
in pancreatic transplantation in the past 4 years because of new
surgical approaches. Najarian and Sutherland have successfully
undertaken a series of living related donor, segmental pancreat-
ic transplants in type-I diabetics who were also recipients of
kidney allografts [511. Longer followup obviously is necessary
for full analysis of the effects of restoration of pancreatic
endocrine function. Thus far, it appears reasonable to conclude
that sustained euglycemia, permitted by the pancreas graft, plus
normal renal function (for one kidney) permits one to achieve
nearly normal living for years. But, by no means is a vascular
catastrophe unavoidable.
DR. HARRINGTON: Are there any studies of the glomerular
basement membrane in young diabetics who have been treated
vigorously for several years with either insulin pumps or
multiple insulin injections to determine whether the anticipated
basement membrane thickening is preventable?
DR. FRIEDMAN: The use of insulin pumps has been too recent
for me to answer your question. Experiments are now being
performed that will produce the needed data. To obtain permis-
sion for repetitive kidney biopsy of asymptomatic type-I diabet-
ics may be difficult, of questionable ethics, and unnecessary.
Other tissues are available for study, including skin and muscle
capillaries. Leakage from retinal capillaries can be quantified by
several techniques. Direct evidence of the value of euglycemia
in protecting the kidney from glomeruloscierosis will be accu-
mulated from serial biopsies of kidney transplants from nondia-
betic into diabetic recipients. Preliminary data indicate that in
the presence of euglycemia, diabetic glomerulopathy is retarded
at least for the first 3 posttransplant years [52].
DR. JERRY MCCAULEY (Research Fellow, Renal Service,
NEMC): If I understood you correctly, you seemed to suggest
that hyperglycemia per se causes the complications of diabetes.
Is this interpretation correct, or could it be an effect of insulin
deficiency for which hyperglycemia is simply a marker?
DR. FRIEDMAN: Yours is an important question, the answer
to which will provide insight into why vasculopathy results
from metabolic inbalance. When I speak of hyperglycemia
being harmful, I mean that glucose levels serve as a convenient
indicator of the rate of tissue injury occurring in diabetics in
poor control. It may very well be that high glucose concentra-
tions cause the buildup of another product, say, glycosylated
albumin, which is in fact responsible for microangiopathy.
While scores of biochemical pertubations have been found in
diabetics, all that have been studied revert to normal when
blood glucose levels are corrected. In this context, for clinical
purposes, a high blood glucose level serves as a marker of all
that is wrong in the diabetic. If correcting blood glucose
reverses the other changes, then whether or not hyperglycemia
is the primary event is of secondary importance.
DR. MICHAEL MADAIO (Renal Service, NEMC): It has been
suggested that the elevated GFR observed in the early phases of
diabetes is in itself damaging. An analogy would be the remnant
kidney model described by Hostetter and Brenner, in which an
increase in single-nephron GFR is associated with the develop-
ment of focal sclerosis [53]. You alluded to some data suggest-
ing that control of hyperglycemia decreases the abnormally high
GFR. Might this be a mechanism whereby euglycemia could
benefit the kidney?
DR. FRIEDMAN: When type-I diabetics are initially regulated
with insulin, there is a decrease in GFR, but not to normal. For
at least the first decade of insulin dependence, GFR continues
to be supernormal. The mechanism for the increased GFR
remains unknown, although excess growth hormone and other
counterregulatory hormones have been suspected as responsi-
ble. Experiments designed to directly tie the blood glucose level
to GFR have been unsuccessful. The well-constructed studies
of Brenner's group, yielding the inference that glomerular
hyperfiltration leads to glomerulosclerosis in the rat remnant
kidney, do not yet sufficiently explain the glomerulopathy
found in diabetics. In a study of patients who have had type-Il
diabetes for 1 to more than 25 years, we found creatinine
clearance to be normal or below normal no matter how long the
patient had been diabetic. We interpreted these results to
indicate that the glomerulosclerosis that occurs in type-I!
diabetes is not always the consequence of long-standing hyper-
filtration [54].
DR. ANDREW S. LEVEY (Renal Service, NEMC): How many
of your uremic or nearly uremic patients are able to achieve self
monitoring and strict control?
DR. FRIEDMAN: In collaboration with Celia Levitz and Son-
dra Hirsch, we are now following about 25 patients who have
accepted a self-monitoring blood glucose control program. Part
of our study's objective is to determine how many patients will
continue on the regimen "permanently."
DR. LEVEY: What are the reasons for failure among those
patients? And what are the optimal methods for selecting
patients to undergo this regimen?
DR. FRIEDMAN: We are beginning to form an impression of
the probable limits of self monitoring for glucose levels. Neither
of 2 overtly psychotic patients was able to accept the rigors of
scheduled finger sticking 4 or more times daily, and both were
treatment failures. Blind patients require cooperation of a
family member or friend to perform repetitive testing. Trans-
plant recipients who welcome the advantages of self monitor-
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ing, which include freedom of meal timing and elimination of
the need to eat "defensively" to avoid "random" hypoglyce-
mic attacks, exhibit decreased adherence to the regimen at
times of serious illnesses such as limb amputation or ocular
surgery. Success in acceptance of self monitoring, with its
annoying finger sticks, is a measure of patient motivation and
understanding. Pregnant women, who understand that euglyce-
mia may protect their baby, apply more than the number of
tests requested and thus evince excellent complicance. Should
we be able to communicate the message that euglycemia will
protect their kidney transplants, many patients may be won
over to the rigors of strict control.
DR. COHEN: You have made only passing reference to type-lI
diabetes. Are there any data to suggest that close control of
blood glucose levels in these patients would have the same
protective potential?
DR. FRIEDMAN: We know surprisingly little about the renal
disease that complicates type-Il diabetes. Although glomerular
lesions apparently indistinguishable from type-I glomerulo-
pathy occur, we can only speculate about how long they take to
develop, and whether progression of microangiopathy in other
organs, especially the retina, correlates to the same degree as in
the type-I patient.
Reprint requests to Dr. E. A. Friedman, Renal Disease Division,
Slate University of New York, Downstate Medical Center, 450 Clark-
son Avenue, Brooklyn, New York 11203, USA
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